classical Hodgkin lymphoma
Haematology · 2024–2024
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| brentuximab vedotin First-line treatment of adult patients with previously untreated CD30+ advanced (Stage III or IV) classical Hodgkin lymphoma in combination with doxorubicin,… | Mar 2024 | Not recommended | input received Leukaemia Foundation |
Who spoke
Leukaemia Foundation
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.